

**Drug Safety and Risk Management Advisory Committee Meeting
and the
Dermatologic and Ophthalmic Drugs Advisory Committee
February 26 & 27, 2004**

Consultants (Voting)

Wilma F. Bergfeld, M.D.
Head of Clinical Research
Dept. of Dermatology
Cleveland Clinic Foundation
9500 Euclid Avenue, Room A61
Cleveland, Ohio 44195-5001

Michael E. Bigby, M.D.
Assistant Professor of Dermatology
Beth Israel Deaconess Medical Center
330 Brookline Avenue
Libby 134
Boston, Massachusetts 02215

Margaret Honein, Ph.D., M.P.H.
Centers for Disease Control and Prevention
National Center on Birth Defects
& Developmental Disabilities
Division of Birth Defects &
Developmental Disabilities
Mailstop E-86
1600 Clifton Road
Atlanta, Georgia 30333

Arthur H. Kibbe., Ph.D.
Department of Pharmaceutical Science
Nesbit School of Pharmacy
Wilkes University
Wilkes-Barre, Pennsylvania 18766

Sarah Sellers, Pharm.D.
121 Rose Terrace
Tower Lakes, Illinois 60010

Amarilys Vega, M.D., Ph.D.
6305 Mellow Twilight Court
Columbia, Maryland 21044

Jurgen Venitz, M.D., Ph.D.
222 W. Brook Run Drive
Richmond, Virginia 23233-6208

Guest Speakers (Non-voting)

Richard K. Miller, Ph.D.
Professor and Associate Chair of
Obstetrics and Gynecology
Director, PEDECS
(NIEHS/NY Teratogen Information Service)
University of Rochester
School of Medicine and Dentistry
601 Elmwood Avenue
Room 5-7550

Rochester, New York 14642-8668 USA
Richard A. Wagner, Pharm.D.
Leader
Kaiser Permanente Drug Use Management
Downey, California

**Drug Safety and Risk Management Advisory Committee Meeting
and the
Dermatologic and Ophthalmic Drugs Advisory Committee**

February 26 & 27, 2004

FDA Staff

Mark Avigan, M.D., C.M.
Director, Division of Drug Risk Evaluation
Office of Pharmacoepidemiology
and Statistical Science
Center for Drug Evaluation and Research
HFD-400
5600 Fishers Lane
Rockville Maryland 20857

Allen Brinker, M.D., M.S.
Lead Medical Officer
Office of Pharmacoepidemiology
and Statistical Science
Office of Drug Safety
Center for Drug Evaluation and Research
HFD-400
5600 Fishers Lane
Rockville Maryland 20857

Gary Buehler, R.Ph.
Director, Office of Generic Drugs
Office of Pharmaceutical Science
Center for Drug Evaluation and Research
HFD-600
5600 Fishers Lane
Rockville Maryland 20857

Jonca Bull, M.D.
Director, Office of Drug Evaluation V
Office of New Drugs
Center for Drug Evaluation and Research
HFD-105
5600 Fishers Lane
Rockville Maryland 20857

Steven Galson, M.D., M.P.H.
Acting Director
Center for Drug Evaluation and Research
HFD-001
5600 Fishers Lane
Rockville Maryland 20857

John Jenkins, M.D.
Director, Office of New Drugs
Center for Drug Evaluation and Research
HFD-020
5600 Fishers Lane
Rockville Maryland 20857

Sandra Kweder, M.D.
Deputy Director, Office of New Drugs
Center for Drug Evaluation and Research
HFD-020
5600 Fishers Lane
Rockville Maryland 20857

Jill Lindstrom, M.D.
Medical Officer
Division of Dermatologic and Dental Drug Products
Office of Drug Evaluation V
Office of New Drugs
Center for Drug Evaluation and Research
HFD-540
9201 Corporate Boulevard
Rockville Maryland 20850

Marilyn Pitts, Pharm.D.
Safety Evaluator
Division of Drug Risk Evaluation
Office of Pharmacoepidemiology
and Statistical Science
Center for Drug Evaluation and Research
HFD-430
5600 Fishers Lane
Rockville Maryland 20857

Paul Seligman, M.D., M.P.H.
Director, Office of Pharmacoepidemiology
and Statistical Science
Center for Drug Evaluation and Research
HFD-030
5600 Fishers Lane
Rockville Maryland 20857

Anne Trontell, M.D., M.P.H.
Deputy Director, Office of Drug Safety
Center for Drug Evaluation and Research
HFD-400
5600 Fishers Lane
Rockville Maryland 20857

Kathleen Uhl, M.D.
Team Leader, Pregnancy Labeling Team
Office of New Drugs
Center for Drug Evaluation and Research
HFD-020
5600 Fishers Lane
Rockville Maryland 20857

Jonathan Wilkin, M.D.
Director
Division of Dermatologic and Dental Drug Products
Office of Drug Evaluation V
Office of New Drugs
Center for Drug Evaluation and Research
HFD-540
9201 Corporate Boulevard
Rockville Maryland 20850

